There’s a lot of hope that artificial intelligence could help speed up the time it takes to make a drug and also increase the rate of success. Several startups have emerged to capitalize on this opportunity. But Insitro is a bit different from some of these other companies, which rely more heavily on machine learning than biology.
Machine learning can speed up the creation of new drugs and unlock the mysteries of major diseases, says Insitro CEO Daphne Koller.
[Photo: Ivan-balvan/iStock]
Comments are closed.